Supplementary Table 2:	Patients with treatment-emergent adverse events of rash and time to onset
of first skin rash in apalutamide-treated arm of TITAN (NCT02489318) – Safety population	
	Apalutamide 	
Analysis set: Safety Analysis Set	524	
		
Subjects with TE Rash	153 (29.2%)	
		
Time (Months) to Onset of First Skin Rash		
N	153	
≤ 12 Months	137 (89.5%)	
12 – ≤ 24 Months	9 (5.9%)	
> 24 Months	7 (4.6%)	
		
Time (Months) to Onset of First Skin Rash		
N	153	
Mean (SD)	5.11 (7.080)	
Median	2.79	
Range	(0.0; 42.5)	

Note: Treatment-emergent adverse events are those that occurred between the date of 1st dose of study drug and date of last dose of study drug plus 30 days.
Note: Adverse events are coded using Medical Dictionary for Regulatory Activities Version 20.0.	
	
SD, standard deviation; TE, treatment-emergent.